inter-trinex emulsionskoncentrat
inter-trade a/s - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 250 g/l trinexapac-ethyl ; (~ 222 g/l trinexapac
moxa emulsionskoncentrat
globachem nv - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 250 g/l trinexapac-ethyl ; (~ 222 g/l trinexapac
primo maxx ii vandopløseligt koncentrat
syngenta nordics a/s - trinexapac-ethyl, trinexapac - vandopløseligt koncentrat - 116,4 g/l trinexapac-ethyl ; (~ 103 g/l trinexapac
primo maxx pro vandopløseligt koncentrat
syngenta nordics a/s - trinexapac-ethyl, trinexapac - vandopløseligt koncentrat - 116,4 g/l trinexapac-ethyl ; (~ 103 g/l trinexapac
stemper emulsionskoncentrat
adama northern europe b.v. - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 175 g/l trinexapac-ethyl ; (~ 156 g/l trinexapac)
cyklokapron 1 g brusetabletter
meda as - tranexamsyre - brusetabletter - 1 g
moddus emulsionskoncentrat
syngenta nordics a/s - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 250 g/l trinexapac-ethyl ; (~ 222 g/l trinexapac
moddus emulsionskoncentrat
3a kemi a/s - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 250 g/l trinexapac-ethyl ; (~ 222 g/l trinexapac
tranexkabi 10 mg/ml infusionsvæske, opløsning
fresenius kabi ab - tranexamsyre - infusionsvæske, opløsning - 10 mg/ml
xenpozyme
sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - andre alimentary tract and metabolism produkter, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.